Reed E C
University of Nebraska Medical Center, Oncology/Hematology, Omaha 68198-3330, USA.
Nebr Med J. 1996 Mar;81(3):48-50.
The benefits of adjuvant systemic therapy in the treatment of early breast cancer are well established. However, many questions remain regarding the appropriate selection of patients and regimens, duration of treatment, timing or sequencing of treatment as well as the role of high-dose chemotherapy or new active drugs such as paclitaxel. Future answers will only come through continued participation in carefully designed clinical research.
辅助性全身治疗在早期乳腺癌治疗中的益处已得到充分证实。然而,在患者和治疗方案的恰当选择、治疗持续时间、治疗时机或顺序以及高剂量化疗或紫杉醇等新型活性药物的作用等方面,仍存在许多问题。未来的答案只能通过持续参与精心设计的临床研究来获得。